Implications for medication safety and adherence in dermato-oncology: The AMBORA care program for oral antitumor therapeutics

Cuba L, Dörje F, Kramer R, Dürr P, Erdmann M, Fromm M, Berking C, Geßner K (2025)

Publication Type: Journal article

Publication year: 2025

Journal

Journal der Deutschen Dermatologischen Gesellschaft Wiley-Blackwell

DOI: 10.1111/ddg.15809

Abstract

Background and Objectives: Dermatological oral antitumor therapeutics (OAT) are often interaction-prone and used in complex regimens. The pharmacological/pharmaceutical care program of the randomized AMBORA trial significantly improved medication safety with various OAT; however, dermato-oncological patients were not included. It was subsequently implemented into clinical routine, including dermato-oncology. We aimed to analyze medication errors and adherence in patients treated with any dermatological OAT. Patients and Methods: Medication errors were characterized, for example, according to their cause (PCNE V9.1). Adherence was assessed using the Medication Event Monitoring System (MEMS® Button) and the MARS-D questionnaire. Primary outcomes were the percentage of resolved OAT-involving errors and Dosing Adherence (DA); proportion of days with correct OAT intake) over 12 weeks. Results: In 92 patients (81.5% melanoma), we detected 1.6 medication errors per patient and 61.6% involved the OAT. Thereof, 89.2% were resolved. Of 52 patients participating in the additional adherence monitoring, 48 were evaluable and reached a median DA of 95.0% and MARS-D score of 25/25. DA was higher in once- vs. twice-daily regimens (p = 0.0127). Conclusions: The interprofessional AMBORA care program in dermato-oncology was associated with the resolution of a large proportion of medication errors and high adherence. Evidence-based medication management and patient counseling by clinical pharmacologists/pharmacists optimizes medication safety in dermato-oncological practice.

Authors with CRIS profile

Lisa Cuba Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie Frank Dörje Apotheke des Universitätsklinikums Rafaela Kramer Department of Dermatology Pauline Dürr Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie Michael Erdmann Department of Dermatology Martin Fromm Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie Carola Berking Lehrstuhl für Haut- und Geschlechtskrankheiten Katja Geßner Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie

Additional Organisation(s)

Tumorzentrum der Universität Erlangen-Nürnberg

How to cite

APA:

Cuba, L., Dörje, F., Kramer, R., Dürr, P., Erdmann, M., Fromm, M.,... Geßner, K. (2025). Implications for medication safety and adherence in dermato-oncology: The AMBORA care program for oral antitumor therapeutics. Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15809

MLA:

Cuba, Lisa, et al. "Implications for medication safety and adherence in dermato-oncology: The AMBORA care program for oral antitumor therapeutics." Journal der Deutschen Dermatologischen Gesellschaft (2025).

BibTeX: Download